Department of Biomedical, Experimental and Clinical Sciences, University of Florence, Careggi University Hospital, Florence, Italy.
High Risk Pregnancy Unit, Careggi University Hospital, Florence, Italy.
Front Endocrinol (Lausanne). 2021 Mar 9;12:630903. doi: 10.3389/fendo.2021.630903. eCollection 2021.
Maternal characteristics and OGTT values of pregnancies complicated by gestational diabetes mellitus (GDM) were evaluated according to treatment strategies. The goal was to identify different maternal phenotypes in order to predict the appropriate treatment strategy.
We conducted a retrospective study among 1,974 pregnant women followed up for GDM in a tertiary referral hospital for high-risk pregnancies (Careggi University Hospital, Florence, Italy) from 2013 to 2018. We compared nutritional therapy (NT) alone (n = 962) NT and insulin analogues (n = 1,012) group. Then, we focused on different insulin analogues groups: long acting (D), rapid acting (R), both D and R. We compared maternal characteristics of the three groups, detecting which factors may predict the use of rapid or long-acting insulin analogue alone combined therapy.
Among women included in the analysis, 51.3% of them needed insulin therapy for glycemic control: 61.8% D, 28.3% combined D and R, and 9.9% R alone. Age >35 years, pre-pregnancy BMI >30, family history of diabetes, previous GDM, altered fasting plasma glucose (FPG), hypothyroidism, and assisted reproductive technologies (ART) were identified as maternal variables significantly associated with the need of insulin therapy. Altered 1-h and 2-h glucose plasma glucose level at OGTT, age >35 years, and previous GDM were found as independent predicting factors for the use of combined therapy with rapid and long acting analogues for glycemic control. On the contrary, pre-pregnancy BMI <25 and normal fasting plasma glucose values at OGTT were found to be significantly associated to the use of rapid insulin analogue only.
A number of maternal and metabolic variables may be identified at the diagnosis of GDM, in order to identify different GDM phenotypes requiring a personalized treatment for glycemic control.
根据治疗策略评估妊娠合并糖尿病(GDM)的母体特征和 OGTT 值。目的是识别不同的母体表型,以预测合适的治疗策略。
我们对 2013 年至 2018 年在意大利佛罗伦萨高危妊娠三级转诊医院(Careggi 大学医院)接受 GDM 随访的 1974 名孕妇进行了回顾性研究。我们比较了单纯营养治疗(NT)组(n=962)和 NT 联合胰岛素类似物(n=1012)组。然后,我们专注于不同的胰岛素类似物组:长效(D)、速效(R)、D 和 R 联合。我们比较了三组的母体特征,检测哪些因素可能预测单独使用速效或长效胰岛素类似物或联合治疗。
在纳入分析的妇女中,51.3%的人需要胰岛素治疗来控制血糖:61.8%使用 D,28.3%联合使用 D 和 R,9.9%单独使用 R。年龄>35 岁、孕前 BMI>30、糖尿病家族史、既往 GDM、空腹血糖(FPG)改变、甲状腺功能减退和辅助生殖技术(ART)被确定为与胰岛素治疗需求显著相关的母体变量。OGTT 时 1 小时和 2 小时血糖水平改变、年龄>35 岁和既往 GDM 是联合使用速效和长效类似物控制血糖的独立预测因素。相反,孕前 BMI<25 和 OGTT 时正常空腹血糖值与仅使用速效胰岛素显著相关。
在诊断 GDM 时,可以识别出许多母体和代谢变量,以识别需要个性化治疗以控制血糖的不同 GDM 表型。